James Darecca - 15 May 2026 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Reporting relationship: EVP, Chief Financial Officer
Issuer ticker: HAE
Reported as of: 15 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2026, 17:34:54 UTC
Prior SEC filing: 05 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas V. Powers, attorney-in-fact for Mr. D'Arecca

Key filing fact

James Darecca filed Form 4 for HAEMONETICS CORP (HAE) on 19 May 2026.

Key facts

This page summarizes James Darecca's Form 4 filing for HAEMONETICS CORP (HAE).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2026, 17:34.

Change

Previous filing in this sequence was filed on 05 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001583903 Primary reporting owner

DArecca James

Relationship: EVP, Chief Financial Officer
Address: 125 SUMMER STREET, BOSTON
Signature: /s/ Thomas V. Powers, attorney-in-fact for Mr. D'Arecca
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HAE transaction

Common Stock

Tax liability

Transaction value
Shares: -2,505
Change %: -9.1%
Price: $56.29^*
Shares after: 25,132
Date: 15 May 2026
Ownership: Direct
Footnotes: F1, F2

HAE transaction

Common Stock

Award

Transaction value
Shares: +29,312
Change %: +117%
Price
Shares after: 54,444
Date: 15 May 2026
Ownership: Direct
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.

Footnote F2

This number includes unvested RSUs previously reported.

Footnote F3

The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three annual installments with forty percent of the total award vesting on the first anniversary of the date of grant, forty percent vesting on the second anniversary of the date of grant and the remaining twenty percent vesting on the third anniversary of the date of grant.

Footnote F4

Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.